U.S. Markets open in 34 mins

The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

Zacks Equity Research
Arconic (ARNC) closed at $25.82 in the latest trading session, marking a -0.69% move from the prior day.

For Immediate Release

Chicago, IL –January 17, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Procter & Gamble PG, NVIDIA NVDA, Bristol-Myers BMY, Deere DE and Ecolab ECL.

Here are highlights from Wednesday’s Analyst Blog:

Top Analyst Reports for Procter & Gamble, NVIDIA and Bristol-Myers

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, NVIDIA and Bristol-Myers. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Procter & Gamble’s shares outperformed the Zacks Soap and Cleaning Materials industry in the past three months, gaining +12.4% vs +5.8%. The Zacks analyst thinks that this can be attributed to the company’s robust earnings history, having outpaced estimates for 14 straight quarters when it reported first-quarter fiscal 2019. Moreover, earnings grew year over year.

Also, sales beat estimates, though it remained flat due to adverse currency fluctuations – which acted as a major deterrent in the first quarter and is likely to remain a concern in the second quarter. The company has been witnessing strained margins for last few quarters due to higher commodity and shipping costs, adverse currency, increased business investments and aggressive pricing from private-label products. Soft baby care business is also a concern.

Nevertheless, the company is focused on improving productivity and cost savings to boost margins. Its focus on product improvement, packaging and marketing initiatives is encouraging.

(You can read the full research report on Procter & Gamble here >>>).

Shares of NVIDIA have underperformed the Zacks General Semiconductor industry over the past year (down -33.3% vs. -11.7%). The Zacks analyst thinks NVIDIA is gaining from its sustained efforts toward attaining a robust position in several emerging industries.

Growth opportunities in ray-traced gaming, rendering, high-performance computing, artificial intelligence (AI) and self-driving cars are expected to be the company’s consistent tailwinds. Rapid adoption of GPUs in the automotive and datacenter markets is a key growth driver.

However, the company is experiencing a rough time due to a string of weaknesses plaguing the semiconductor market recently. The end of the cryptocurrency mining boom weakened demand for its GPUs. The company is hurt by weakness in the Gaming segment, which is affected by an excess inventory of midrange Pascal products.

(You can read the full research report on NVIDIA here >>>).

Bristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year, losing -19.6% vs. -1.2%. The Zacks analyst thinks Bristol-Myers' blockbuster immuno-oncology drug Opdivo’s performance is being boosted by the uptake in new indications - first line renal cell carcinoma and adjuvant melanoma.

The company is looking to expand Opdivo’s label further which should boost performance. Eliquis is expected to drive growth, owing to increases in market share in the novel oral anticoagulant (NOAC) market. The label expansion of other drugs like Sprycel and Empliciti also bode well for the company and should boost performance. The recently announced acquisition of Celgene should further strengthen the company’s oncology franchise.

However, the FDA extension of the PDUFA date for the sBLA seeking approval of Opdivo+Yervoy as a treatment for first-line non-small cell lung cancer was disappointing given the market potential. Competition is stiff as well.

(You can read the full research report on Bristol-Myers here >>>).

Other noteworthy reports we are featuring today include Deere and Ecolab.

More Stock News: This Is Bigger than the iPhone!                  

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. 

Click here for the 6 trades >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                                   

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ecolab Inc. (ECL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research